Last reviewed · How we verify
NCT06880380: HIV-CAR-T
The Efficacy and Safety Study of CAR-T Cells for Functional Cure in HIV-1/AIDS Patients
Phase 1 trial testing HIV-CAR-T in HIV Infected Individuals in 3 participants. Currently enrolling.
31 March 2026
Quick facts
| Lead sponsor | Institute of Hematology & Blood Diseases Hospital, China |
|---|---|
| Phase | Phase 1 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 3 |
| Start date | 1 September 2025 |
| Primary completion | 31 March 2026 |
| Estimated completion | 1 July 2026 |
| Sites | 1 location across China |
Drugs / interventions tested
- HIV-CAR-T — full drug profile →
Conditions studied
- HIV Infected Individuals — all drugs for HIV Infected Individuals →
- HIV — all drugs for HIV →
Sponsor
Institute of Hematology & Blood Diseases Hospital, China
Who can join
Adults 18 to 65, any sex, with HIV Infected Individuals or HIV. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Autologous CAR-T cell therapy in HIV-1/AIDS patients
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
Chimeric Antigen Receptor Immunotherapy for Infectious Diseases: Current Advances and Future Perspectives.
Kourti M, Evangelidis P, Roilides E, Iosifidis E. · · 2025 · cited 3× · PMID 40872284 · DOI 10.3390/pathogens14080774 -
Chimeric antigen receptor T‑cell therapy in chronic viral infections: a review.
Han Q, Zhang X, Chen L, Zhang Y. · · 2026 · PMID 41535864 · DOI 10.1186/s12967-025-07582-0
Verify or expand the search:
- PubMed search for NCT06880380
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for HIV Infected Individuals
Currently open trials in the same condition.
- NCT06762730 — Zoledronic Acid for the Prevention of TDF-sparing ART-induced Bone Mass Density Loss in Treatment-naive HIV Positive Ind · Phase 4 · recruiting
Other Institute of Hematology & Blood Diseases Hospital, China trials
Trials by the same sponsor.
- NCT06991920 — Immune-targeted Combination With Chemotherapy for Acute Leukemia of Ambiguous Lineage · NA · not yet recruiting
- NCT07407010 — BCMA/CD3 Bispecific Antibody as Bridging Therapy Before CAR-T Cell Infusion in RRMM · Phase 1 · not yet recruiting
- NCT07407140 — VAG Versus Standard Chemotherapy With FLT3 Inhibitor in Adult Patients With FLT3-Mutated AML · Phase 3 · not yet recruiting
- NCT07454226 — ABL/JAK Inhibitors With Chemotherapy and Venetoclax for Ph-like ALL · NA · not yet recruiting
- NCT07490288 — Venetoclax, Azacitidine and Liposomal Mitoxantrone for Newly Diagnosed AML · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06880380 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Institute of Hematology & Blood Diseases Hospital, China
- Last refreshed: 5 March 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06880380.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing